RALEIGH, North Carolina, Jan. 24, 2025 (GLOBE NEWSWIRE) — Die Rückkehr an den Arbeitsplatz nach einer Krebsdiagnose ist mit vielen großen Herausforderungen verbunden – körperliche Erschöpfung, emotionale [...] Read more »
Workplace Options lance un programme complet et compatissant de retour au travail pour les personnes ayant survécu à un cancer
RALEIGH, Caroline du Nord, 24 janv. 2025 (GLOBE NEWSWIRE) — Le retour au travail après un diagnostic de cancer est un parcours semé d’embûches qui mêle fatigue physique, obstacles émotionnels et [...] Read more »
Workplace Options Lança Programa Abrangente e Compassivo de Retorno ao Trabalho para Sobreviventes de Câncer
RALEIGH, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) — O retorno ao trabalho após um diagnóstico de câncer é uma jornada repleta de desafios – fadiga física, obstáculos emocionais e [...] Read more »
SoftSmile and ClearCorrect Announce Settlement
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) — SoftSmile, Inc., ClearCorrect Operating, LLC, and Institut Straumann AG announce that they have amicably settled all litigation and legal disputes between them. The companies [...] Read more »
Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors
RALEIGH, N.C., Jan. 23, 2025 (GLOBE NEWSWIRE) — Returning to work after a cancer diagnosis is a journey fraught with challenges—physical fatigue, emotional hurdles, and workplace reintegration complexities. To [...] Read more »
Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors
RALEIGH, N.C., Jan. 23, 2025 (GLOBE NEWSWIRE) — Returning to work after a cancer diagnosis is a journey fraught with challenges—physical fatigue, emotional hurdles, and workplace reintegration complexities. To [...] Read more »
Brains Bioceutical Expande Oferta de Canabinóides Líder do Setor com D9-THC e CBN, Abrindo Novas Fronteiras para o Desenvolvimento de Medicamentos
VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (Brains Bio), líder global em Ingredientes Farmacêuticos Ativos (APIs) de canabinóides naturais e compatíveis com [...] Read more »
Brains Bioceutical weitet das branchenführende Cannabinoid-Angebot auf D9-THC und CBN aus, um neue Grenzen in der Wirkstoffentwicklung zu erschließen
VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), ein weltweit führendes Unternehmen für natürliche GMP–konforme cannabinoide Pharmawirkstoffe (API), gibt die [...] Read more »
Brains Bioceutical élargit son offre de cannabinoïdes leaders sur le marché avec le D9-THC et le CBN, et ouvre ainsi de nouvelles possibilités en matière de développement de médicaments
VANCOUVER, Colombie–Britannique, 18 déc. 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), leader mondial dans la fabrication d’ingrédients pharmaceutiques actifs (IPA) à base de [...] Read more »
Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development
VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP–compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the expansion of its [...] Read more »